Published in final edited form as:

J Neurovirol. 2012 December ; 18(6): 471–478. doi:10.1007/s13365-012-0125-y.

Possible Role of Interleukin-17 in a Prime/Challenge Model of Multiple Sclerosis

Jane E. Libbey, MS¹, Ikuo Tsunoda, MD, PhD^{2,3}, and Robert S. Fujinami, PhD^{1,*}

¹Department of Pathology University of Utah School of Medicine 30 North 1900 East, 3R330 SOM Salt Lake City, Utah 84132

²Department of Microbiology and Immunology, Louisiana State University Health Sciences Center 1501 Kings Highway Shreveport, LA 71130

³Center for Molecular & Tumor Virology Louisiana State University Health Sciences Center 1501 Kings Highway Shreveport, LA 71130

Abstract

No one single pathogen has been identified as the causative agent of multiple sclerosis (MS). Alternately, the likelihood of an autoimmune event may be nonspecifically enhanced by different infectious agents. In a novel animal model of MS, SJL/J mice primed through infection with a recombinant vaccinia virus (VV) encoding myelin proteolipid protein (PLP) (VV_{PLP}) were susceptible to a central nervous system (CNS) inflammatory disease following administration of a nonspecific immunostimulant [complete Freund's adjuvant (CFA) plus *Bordetella pertussis* (BP)]. Mononuclear cells isolated from the brains, but not the spleens, of VV_{PLP}-primed CFA/BP challenged mice produced interleukin (IL)-17 and interferon- γ and transferred a CNS inflammatory disease to naïve SJL/J mice. Administration of curdlan, a T helper 17 cell inducer, unexpectedly resulted in less severe clinical and histological signs of disease, compared to CFA/BP challenged mice, despite the induction of IL-17 in the periphery. Further examination of the VV_{PLP}-prime CFA/BP challenge model may suggest new mechanisms for how different pathogens associated with MS can protect or enhance disease.

Keywords

Autoimmunity; CNS Inflammatory Demyelinating Diseases; Experimental Autoimmune Encephalomyelitis; Multiple Sclerosis; Theiler's Murine Encephalomyelitis Virus; Vaccination

Introduction

Multiple sclerosis (MS) is an inflammatory, demyelinating, autoimmune disease of the central nervous system (CNS) (Compston and Coles 2008). The etiology of MS is currently unknown; however, microbial infections have been shown to play a role in disease exacerbations [(Kriesel and Sibley 2005), reviewed in (Libbey and Fujinami 2010)]. Despite extensive investigation, no single causative pathogen has been identified for MS. A proposed alternate hypothesis is that many infectious agents nonspecifically enhance the likelihood of an autoimmune event (Tsunoda et al. 2007; von Herrath et al. 2003). This hypothesis would require a two-step process. The first “priming” step would involve the *de novo* activation of autoreactive T cells through molecular mimicry. Molecular mimicry is

*Corresponding to: Robert S. Fujinami, PhD Department of Pathology University of Utah School of Medicine 30 North 1900 East, 3R330 SOM Salt Lake City, Utah 84132 Phone: 801-585-3305 FAX: 801-585-3311 Robert.Fujinami@hsc.utah.edu.

cross-reactivity between self and microbial epitopes during a microbial infection (Cusick et al. 2012; Fujinami et al. 1983; Fujinami and Oldstone 1985; Libbey et al. 2007). The second “challenge” step would involve the nonspecific activation of pre-existing autoreactive T cells through bystander activation. Bystander activation is caused by inflammatory responses, such as the production of cytokines, elicited by nonspecific immunostimulants or irrelevant infections (McCoy et al. 2006).

Previously, our group demonstrated that SJL/J mice primed through infection with a recombinant vaccinia virus (VV) encoding myelin proteolipid protein (PLP) (VV_{PLP}) were susceptible to the development of a CNS inflammatory disease following administration of a nonspecific immunostimulant consisting of complete Freund's adjuvant (CFA) plus *Bordetella pertussis* (BP) cells (Theil et al. 2001; Tsunoda et al. 2007). The VV_{PLP} construct, which is a virus encoding a self protein, mirrors a molecular mimic, which is a virus encoding an immunologically cross-reactive epitope, and infection with this construct alone does not lead to the development of overt clinical or histological autoimmune disease (Theil et al. 2001). Secondary challenge of these “primed” mice with CFA/BP resulted in clinically and histologically evident CNS inflammatory disease, suggesting that bystander activation can function on antigen-specific cells originally induced by molecular mimicry (Theil et al. 2001; Tsunoda et al. 2007).

Two common animal models of MS are: Theiler's murine encephalomyelitis virus (TMEV) infection, which is a viral model, and experimental autoimmune encephalomyelitis (EAE), which is an autoimmune disease model [reviewed in (Tsunoda and Fujinami 1996)]. The VV_{PLP}-prime CFA/BP challenge model, which mirrors a molecular mimic, is similar to the TMEV infection model in that both involve a live viral infection, and the clinical signs induced by this prime/challenge model more closely resemble clinical signs induced by TMEV (impaired righting reflex) than typical EAE signs of disease. Molecular mimicry has been shown to play a pathogenic role in TMEV infection, where anti-TMEV serum and antibody against TMEV capsid protein cross-react with a myelin component, contributing to disease exacerbation [reviewed in (Tsunoda and Fujinami 1999)]. The VV_{PLP}-prime CFA/BP challenge model is also similar to the EAE model in that the VV construct encodes PLP and EAE can be induced through inoculation with CNS proteins, to include PLP, emulsified in CFA [reviewed in (Tsunoda and Fujinami 1996)].

MS is thought to be driven by both the T helper (Th) 1 and Th17 subsets of CD4⁺ T cells [reviewed in (Chen et al. 2012; Jadidi-Niaragh and Mirshafiey 2011)]. Likewise, the disease induced by TMEV infection appears to be partly dependent on CD4⁺ T cells [reviewed in (Tsunoda and Fujinami 1996)], and both the Th1 and Th17 subsets have been implicated in disease development following TMEV infection of susceptible mouse strains (Hou et al. 2009; Pullen et al. 1994). Increasing the Th1 response, by injecting interferon (IFN)- γ into the brain, enhanced the development of disease following TMEV infection (Pullen et al. 1994), and Th17 cells and the cytokine they produce, interleukin (IL)-17, were demonstrated to be induced and to play an immunomodulatory role in TMEV infection (Hou et al. 2009). EAE is also predominantly mediated by autoreactive CNS specific CD4⁺ T cells in that, in general, CD4⁺ Th1 cells and Th1-type cytokines [IL-2, lymphotoxin, IFN- γ] promote EAE, and until recently CD4⁺ Th1 cells were thought to be the main effector cells responsible for the disease [reviewed in (Tsunoda and Fujinami 1996)]. However, Th17 cells are also effector cells in EAE (Harrington et al. 2005). The relative role of the Th1 or Th17 cell types in the pathogenesis of disease is still under investigation [reviewed in (Fletcher et al. 2010)].

Two related family members of IL-17, IL-17A and IL-17F, are produced by Th17 cells and Th17 cells also produce the proinflammatory cytokines IL-21, IL-22, IL-26 and tumor necrosis factor (TNF)- α [reviewed in (Jadidi-Niaragh and Mirshafiey 2011)]. Curdlan, a

Th17 cell inducer, is an extracellular polysaccharide produced by *Agrobacterium* species [reviewed in (Laroche and Michaud 2007; McIntosh et al. 2005)]. Antigen-presenting cells, macrophages and dendritic cells, which express the C-type lectin, dectin-1, on their cell surface, can be activated by curdlan (LeibundGut-Landmann et al. 2007; Yoshitomi et al. 2005). Curdlan-induced dectin-1 signaling promotes dendritic cell maturation and secretion of proinflammatory cytokines. In turn, activated dendritic cells and proinflammatory cytokines are involved in the differentiation of the IL-17-producing subset of CD4⁺ effector T cells (Th17 cells) (LeibundGut-Landmann et al. 2007; Yoshitomi et al. 2005).

In the current study, the ability of mononuclear cells (MNCs), isolated from the brains, but not the spleens, of mice primed with VV_{PLP} and challenged with CFA/*BP*, to transfer a CNS inflammatory disease to naïve SJL/J mice was demonstrated. In addition, a possible role for IL-17 in transfer of disease was observed. Finally, the ability of curdlan, a Th17 cell inducer, to modulate the resultant CNS inflammatory disease was examined. Our initial hypothesis was that curdlan would exacerbate the CNS inflammatory disease, since curdlan induces Th17 cells and Th17 cells function as effector cells in MS, TMEV and EAE disease; however, curdlan was found to ameliorate both the clinical and histological signs of disease despite the induction of IL-17 in the periphery.

Materials and Methods

Animal experiments

Four- to 6-week-old female SJL/J mice were purchased from the Jackson Laboratory (Bar Harbor, ME). The care and use of the mice were in accordance with the guidelines prepared by the committee on Care and Use of Laboratory Animals, Institute of Laboratory Animals Resources, National Research Council.

Mice were infected intraperitoneally (i.p.) with 1×10^6 plaque forming units of VV_{PLP} (encoding rat PLP) in 200 μ l phosphate-buffered saline (PBS) (Barnett et al. 1993). Five weeks after VV_{PLP} infection, mice were injected subcutaneously (s.c.) at the base of the tail with 200 μ l of CFA, which was a mixture of equal volumes PBS and Imject® Freund's incomplete adjuvant (IFA, Pierce Biotechnology, Rockford, IL) containing 2 mg/ml *Mycobacterium tuberculosis* H37 Ra (Difco Laboratories, Detroit, MI). Mice also received 2 intravenous injections (on the same day as the CFA injection and on the following day) of 5×10^9 *BP* cells (Michigan Department of Public Health, Lansing, MI) in 100 μ l PBS. Mice were followed for clinical signs. Three weeks after CFA/*BP* challenge mice were sacrificed. The tissues from some of these mice were harvested for histology (see below). The brains and spleens from others of these mice were harvested and MNCs were isolated with Percoll™ (GE Healthcare Bio-Sciences, Piscataway, NJ). MNCs isolated from the brains of 3 mice were pooled. The MNCs were stimulated with concanavalin A (Con A, Sigma-Aldrich, St. Louis, MO), expanded with the Dynabeads® Mouse CD3/CD28 T Cell Expander (Invitrogen, San Diego, CA), as per the manufacturer's recommendation, in the presence of IL-2 (10 U/ml, BD Pharmingen, San Jose, CA), or not treated for 3 weeks *in vitro*. Supernatant was saved for enzyme-linked immunosorbent assays (ELISAs) (see below), and MNCs (1×10^6 or 1×10^7 cells in 200 μ l RPMI media per mouse) from the CD3/CD28 expanded cultures were transferred i.p. into naïve SJL/J mice. Mice were followed for clinical signs and sacrificed 3 weeks after transfer.

Additional mice were infected with VV_{PLP}, as described above. Five weeks after VV_{PLP} infection, mice were injected s.c. with 200 μ l of curdlan (5 mg/ml in PBS, Wako Chemicals, Richmond, VA) mixed with an equal volume of IFA. Mice were followed for clinical signs and sacrificed at 2-3 weeks post curdlan/IFA challenge.

Additional mice were infected with VV_{PLP}, as described above. Five weeks after VV_{PLP} infection, mice were injected i.p. with 200 µl curdlan (25 mg/ml) in PBS alone. Mice were followed for clinical signs and sacrificed at 2 weeks post curdlan/PBS challenge.

Clinical signs of disease in mice were evaluated through weight change and by an impaired righting reflex test, which are commonly used to evaluate disease in the TMEV inflammatory disease model of MS (Rauch et al. 1987; Tsunoda et al. 2001). When the proximal end of the mouse's tail is grasped and twisted to the right and then to the left, a healthy mouse resists being turned over (score of 0). If the mouse is flipped onto its back but immediately rights itself on one side or both sides, it is given a score of 1 or 1.5, respectively. If it rights itself in 1 to 5 seconds, the score is 2. If righting takes more than 5 seconds, the score is 3.

Histology

Mice were euthanized with isoflurane at the time points indicated above. Animals were perfused with PBS followed by 4% paraformaldehyde. Harvested brains were divided coronally into five portions and spinal cords were divided transversely into 12 portions. Tissues were embedded in paraffin. Four micrometer thick tissue sections were cut, mounted on slides and stained with Luxol fast blue. Neuropathology was scored, in a blinded fashion, as previously described, with slight modification as follows: 0, no lesions; 1, meningeal thickening, or MNC and/or polymorphonuclear cell collection in the meninges, or a small number of T cells detected in the meninges by immunohistochemistry against CD3; 2, perivascular cuffing in the parenchyma and/or meninges (Tsunoda et al. 1998; Tsunoda et al. 2000; Tsunoda et al. 2007). T cells were visualized on serial paraffin sections by the avidin-biotin peroxidase complex (ABC) technique, using anti-CD3e antibody (following trypsinization, 1:30 dilution, DakoCytomation, Carpinteria, CA), as previously described (Tsunoda et al. 2007).

Serum and supernatant ELISAs

Mice were bled when sacrificed. The concentration of IL-17A was measured, in duplicate, in mouse sera and MNC tissue culture supernatants (see above) using the Mouse IL-17A ELISA MAXTM Deluxe Set (Biolegend, San Diego, CA) according to the manufacturer's recommendations. The concentration of IFN-γ was measured, in duplicate, in MNC tissue culture supernatants using the BD OptEIATM Mouse IFN-γ ELISA Set (BD Pharmingen) according to the manufacturer's recommendation.

Statistical analysis

The StatView program (SAS Institute Inc., Cary, NC) was used for all statistical analyses performed. Analysis of variance (ANOVA), followed when indicated by the Fisher's Protected Least Significant Difference (Fisher's PLSD) post hoc test, was used to determine group differences for continuous data (weight, IL-17 ELISA). The unpaired two-group Mann-Whitney *U* test was performed for all nonparametric analyses (righting reflex score, neuropathology score).

Results

Transfer of disease, via MNC transfer, from VV_{PLP}-primed CFA/BP challenged mice to naïve mice

Previously, we demonstrated that administration of the nonspecific immunostimulant, CFA/BP, induced disease in SJL/J mice subclinically primed with VV_{PLP} (Theil et al. 2001; Tsunoda et al. 2007). Here we tested the ability of MNCs, isolated from the brains and spleens of these mice, to transfer disease. Isolated MNCs were expanded *in vitro* in the

presence of CD3/CD28 beads prior to transfer. The mice received either 1×10^7 expanded spleen MNCs alone or 1×10^6 expanded brain MNCs in addition to the 1×10^7 expanded spleen MNCs. The recipient mice were weighed and scored for righting reflex, both clinical signs of disease, daily for 3 weeks, at which point the animals were sacrificed and brains and spinal cords were processed and scored for neuropathology. Over the course of the 3 weeks post MNC transfer, clinical signs of disease were not readily evident. Differences in weight change, between the mice receiving brain MNCs and the mice receiving spleen MNCs alone, were not large and only reached significance on four days, three days on which the mice receiving brain MNCs had a greater weight gain [days 2 and 4 ($p < 0.05$, ANOVA) and day 9 ($p < 0.01$, ANOVA)] and one day on which the mice receiving the spleen MNCs alone had a greater weight gain [day 17 ($p < 0.05$, ANOVA)] (Figure 1a). The righting reflex scores were low overall and although the mice receiving brain MNCs tended to have higher scores than the mice receiving spleen MNCs alone, the differences were not significant (Figure 1b, $p > 0.05$, Mann-Whitney *U*). Upon examination of the neuropathology, however, it was found that the mice receiving brain MNCs had higher neuropathology scores in both the brain and spinal cord, compared to the mice receiving spleen MNCs alone (Figure 2). This difference was significant in the brain ($p < 0.05$, Mann-Whitney *U*). Demyelination was not observed (data not shown). Therefore, although clinical signs of disease were not readily apparent, the transfer of MNCs isolated from the brains of VV_{PLP}-primed CFA/BP challenged mice resulted in significant neuropathology, mainly in the brain, whereas the transfer of only MNCs isolated from the spleens of VV_{PLP}-primed CFA/BP challenged mice did not.

Cytokine production by brain and spleen MNCs

The ability of the brain MNCs to transfer CNS disease may rest on the types and levels of cytokines produced by these cells. The concentrations of IL-17A and IFN- γ produced and released into the cell culture supernatant by brain and spleen MNCs were assayed by ELISA. Spleen MNCs stimulated with Con A (positive control) were found to produce a large amount of IL-17A (1478 pg/ml) in comparison to unstimulated spleen MNCs [no treatment (No Tx), 48 pg/ml] (Figure 3a). Likewise, spleen MNCs stimulated with Con A were found to produce a large amount of IFN- γ (558 pg/ml) in comparison to unstimulated spleen MNCs (No Tx, 56 pg/ml) (Figure 3b). Spleen MNCs expanded with CD3/CD28 beads produced a very small amount of IL-17A (5 pg/ml) and some IFN- γ (83 pg/ml), whereas brain MNCs expanded with CD3/CD28 beads produced a larger amount of IL-17A (209 pg/ml) and IFN- γ (425 pg/ml) (Figure 3). Therefore, the brain MNCs that were able to transfer disease were found to also produce IL-17 and IFN- γ .

Curdlan administration resulted in less severe clinical signs of disease

Here we tested the ability of curdlan, an IL-17 inducer, to modulate the disease by replacing the CFA/BP challenge with either curdlan/IFA or curdlan/PBS. An initial examination of these mice showed that 100% of the curdlan/IFA challenged mice and 40% of the curdlan/PBS challenged mice had mild righting reflex disturbances (Libbey et al. 2010). However, when the weight changes (Figure 4a) and righting reflex scores (Figure 4b), both clinical signs of disease, for the curdlan/IFA and curdlan/PBS challenged mice were compared on a daily basis to the CFA/BP challenged mice, with 5 to 19 mice per group, curdlan administration resulted in less severe disease. The VV_{PLP}-primed CFA/BP challenged mouse group had significantly greater weight loss on days 7 ($p < 0.001$, ANOVA, Fisher's PLSD), 11 and 12 ($p < 0.0001$, ANOVA, Fisher's PLSD), and 13 ($p < 0.01$, ANOVA, Fisher's PLSD) post secondary challenge than both the VV_{PLP}-primed curdlan/IFA challenged and the VV_{PLP}-primed curdlan/PBS challenged mouse groups (Figure 4a). On day 6 post secondary challenge, the VV_{PLP}-primed curdlan/PBS challenged mouse group had significantly greater weight gain than both the VV_{PLP}-primed CFA/BP challenged and

the VV_{PLP}-primed curdlan/IFA challenged mouse groups (Figure 4a, $p < 0.01$, ANOVA). For righting reflex, the VV_{PLP}-primed CFA/*BP* challenged mouse group had significantly higher righting reflex scores than the VV_{PLP}-primed curdlan/IFA challenged and the VV_{PLP}-primed curdlan/PBS challenged mouse groups at days 12 and 13 post secondary challenge (Figure 4b, $p < 0.05$, Mann-Whitney *U*). Therefore, when CFA/*BP* secondary challenge of VV_{PLP}-primed SJL/J mice was replaced with curdlan/IFA or curdlan/PBS secondary challenge, the mice developed less severe disease.

Curdlan administration induced only mild neuropathology

Neuropathology was scored, as described in the methods, to determine whether neuropathology in the brains and spinal cords correlated with the clinical signs of disease. In general, the brains of all the groups (3 to 14 mice per group) scored higher for neuropathology than the spinal cords (Figure 5). The VV_{PLP}-primed curdlan/PBS challenged mouse group tended to have lower neuropathology scores in both the brains and spinal cords in comparison to the VV_{PLP}-primed CFA/*BP* challenged and the VV_{PLP}-primed curdlan/IFA challenged mouse groups, although the differences between the groups did not reach significance (Figure 5, $p > 0.05$, Mann-Whitney *U*). At least in the case of the VV_{PLP}-primed curdlan/PBS challenged mouse group, neuropathology was milder and this correlated with the clinical signs of disease. Demyelination was not observed (data not shown).

Curdlan administration induced IL-17 in the periphery

Curdlan has been shown to induce Th17 cells, which produce the signature cytokine, IL-17 (Zepp et al. 2011). For this reason, the levels of IL-17A in the sera were assayed by ELISA to confirm that curdlan administration resulted in an increase in the production of IL-17 in the periphery. The level of IL-17A in the sera of the VV_{PLP}-primed CFA/*BP* challenged mouse group was significantly lower than the level of IL-17A in the sera of both the VV_{PLP}-primed curdlan/IFA challenged and the VV_{PLP}-primed curdlan/PBS challenged mouse groups, with 9 to 16 mice per group (Figure 6, $p < 0.05$, ANOVA, Fisher's PLSD). Therefore, the administration of curdlan by two different routes (s.c. and i.p.) and in the presence of IFA or PBS resulted in an increase in the levels of IL-17 in the periphery.

Discussion

Previously, our group demonstrated that SJL/J mice subclinically primed with VV_{PLP} did not develop disease, but were susceptible to the development of a CNS inflammatory disease following secondary challenge with CFA/*BP* (Theil et al. 2001; Tsunoda et al. 2007). Further examination of this prime/challenge model of MS will expand our knowledge of the mechanism by which it may be possible for many different pathogens to be associated with MS. Towards this end, we examined the ability of MNCs, isolated from the brains and spleens of these VV_{PLP}-primed CFA/*BP* challenged mice, to both transfer disease and to produce IL-17 and IFN- γ , as a means of elucidating the encephalitogenic nature and phenotype of these MNCs. The MNCs isolated from the brains, but not the spleens, of these primed/challenged mice were found to both produce IL-17 and IFN- γ (Figure 3) and to induce significant neuropathology within the brains of naïve SJL/J mice (Figure 2), upon adoptive transfer, even in the absence of readily apparent clinical signs of disease (Figure 1). Therefore, encephalitogenic cells were present within the brains of the VV_{PLP}-primed CFA/*BP* challenged mice and a subset of these cells were of the Th17 subset of CD4⁺ T cells that has recently been implicated as effector cells in the EAE (Harrington et al. 2005) and TMEV models (Hou et al. 2009).

As examination of the MNCs suggested a role for IL-17, and therefore Th17 cells, in the development of the CNS inflammatory disease in VV_{PLP}-primed CFA/*BP* challenged mice, curdlan administration was employed as a means of further elucidating the encephalitogenic role of Th17 cells in this prime/challenge model. Curdlan induces Th17 cells [reviewed in (Laroche and Michaud 2007; McIntosh et al. 2005)], which have been implicated as effector cells in the EAE (Harrington et al. 2005) and TMEV models (Hou et al. 2009). Therefore, one would hypothesize that curdlan administration would exacerbate the CNS inflammatory disease; however, curdlan administration actually resulted in less severe disease, compared to CFA/*BP* injection. VV_{PLP}-primed mice were injected with curdlan, either s.c. in IFA or i.p. in PBS. Curdlan administration, via two different routes, in two different forms (IFA or PBS) and at two different concentrations, resulted in a reduction in clinical signs of disease (Figure 4), and resulted in a reduction in neuropathology within the brains, at least in the VV_{PLP}-primed curdlan/PBS challenged mice (Figure 5). The VV_{PLP}-primed curdlan/PBS challenged mice received 10 times more curdlan than the VV_{PLP}-primed curdlan/IFA challenged mice (5 mg/mouse and 500 µg/mouse, respectively), which may explain the difference in the ability to reduce neuropathology in the brain between the two curdlan groups.

Curdlan was administered peripherally by two different routes: s.c. and i.p. In order to confirm the induction of Th17 cells in the periphery, IL-17A, the signature cytokine produced by Th17 cells, was assayed in the sera by ELISA. IL-17A, and therefore Th17 cells, were found to be induced in the periphery of VV_{PLP}-primed mice through both s.c. and i.p. administration of curdlan (Figure 6). The induction of Th17 cells and IL-17A in the brains of VV_{PLP}-primed curdlan challenged mice was not determined.

The question remains: why did curdlan administration result in less severe disease instead of exacerbating disease as expected? The effect of curdlan administration may actually depend on many different factors. Some of these factors may include the timing and route of curdlan administration, the concentration of curdlan administered, the type of CNS inflammatory inducer used and the type of CNS inflammation induced. In this study of curdlan administration in VV_{PLP}-primed mice, the timing of curdlan administration was consistent at 5 weeks post VV_{PLP} infection, at which time the VV_{PLP} has been cleared. The route of administration was consistent in that both s.c. and i.p. are peripheral injections. As stated above, the VV_{PLP}-primed curdlan/PBS challenged mice received 10 times more curdlan than the VV_{PLP}-primed curdlan/IFA challenged mice. Therefore, for the factors pertaining to curdlan, only the concentration of curdlan varied to any great extent. The inclusion of IFA as an adjuvant for the curdlan may also have played a role in disease modulation. Finally, in the case of the factors pertaining to the CNS inflammatory disease, the VV_{PLP}-prime CFA/*BP* challenge model may vary a great deal from the EAE and TMEV models. This is evidenced by the fact that VV_{PLP} infection did not induce disease, but did increase the susceptibility of the mice to the development of a CNS inflammatory disease following secondary challenge with CFA/*BP* (Theil et al. 2001; Tsunoda et al. 2007).

This examination of the effect of curdlan administration was not the first time that the reverse of what was expected was seen following an attempt to modulate the CNS inflammatory disease that develops in this prime/challenge model. Previously, VV_{PLP}-primed mice were injected with IL-12 at 5 weeks post VV_{PLP} infection (Tsunoda et al. 2007). IL-12 has been reported to enhance EAE (Gran et al. 2004), through its role in the generation of CD4⁺ Th1 cells [reviewed in (Petermann and Korn 2011)], which were the effector CD4⁺ T cells originally implicated in EAE. At 3 weeks post secondary challenge, none of the IL-12-injected mice developed clinical signs or substantial CNS pathology (Tsunoda et al. 2007).

Further examination of the VV_{PLP}-prime CFA/*BP* challenge model may suggest new, unexpected mechanisms for how many different viruses and microbes associated with MS can protect or enhance disease (Fujinami 2001). Towards this end, we are currently investigating: 1) whether CNS infiltrates are derived from transferred MNCs; 2) the phenotypes and cytokine profiles of CNS infiltrates in both MNC recipient mice and curdlan treated mice; and 3) the role of IL-17 through *in vivo* administration of blocking antibody against IL-17.

Acknowledgments

We thank J. Lindsay Whitton, MD, PhD, and Matthew F. Cusick, PhD, for many helpful discussions, and Nikki J. Kennett, MS, Daniel J. Doty, BS, Braden T. McElreath, Lincoln R. Neugebauer and Robert Greenhalgh, BS, for excellent technical assistance. We are grateful to Mr. Daniel J. Harper for preparation of the manuscript. This work was supported by NIH grants AI058105-05 (RSF), R21NS059724, P20-RR018724 and 8P20 GM103433-10 (IT).

References

- Barnett LA, Whitton JL, Wada Y, Fujinami RS. Enhancement of autoimmune disease using recombinant vaccinia virus encoding myelin proteolipid protein [published erratum appears in *J Neuroimmunol* 48:120, 1993]. *J Neuroimmunol*. 1993; 44:15–25. [PubMed: 7684398]
- Chen SJ, Wang YL, Fan HC, Lo WT, Wang CC, Sytwu HK. Current status of the immunomodulation and immunomediated therapeutic strategies for multiple sclerosis. *Clin Dev Immunol*. 2012; 2012:970789. Doi: 10.1155/2012/970789. [PubMed: 22203863]
- Compston A, Coles A. Multiple sclerosis. *Lancet*. 2008; 372:1502–1517. Doi: 10.1016/S0140-6736(08)61620-7. [PubMed: 18970977]
- Cusick MF, Libbey JE, Fujinami RS. Molecular mimicry as a mechanism of autoimmune disease. *Clin Rev Allergy Immunol*. 2012; 42:102–111. Doi: 10.1007/s12016-011-8294-7. [PubMed: 22095454]
- Fletcher JM, Lalor SJ, Sweeney CM, Tubridy N, Mills KHG. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. *Clin Exp Immunol*. 2010; 162:1–11. Doi: 10.1111/j.1365-2249.2010.04143.x. [PubMed: 20682002]
- Fujinami RS. Viruses and autoimmune disease--two sides of the same coin? *Trends Microbiol*. 2001; 9:377–381. Doi: 10.1016/S0966-842X(01)02097-2. [PubMed: 11514220]
- Fujinami RS, Oldstone MBA. Amino acid homology between the encephalitogenic site of myelin basic protein and virus: Mechanism for autoimmunity. *Science*. 1985; 230:1043–1045. [PubMed: 2414848]
- Fujinami RS, Oldstone MBA, Wroblewska Z, Frankel ME, Koprowski H. Molecular mimicry in virus infection: Crossreaction of measles virus phosphoprotein or of herpes simplex virus protein with human intermediate filaments. *Proc Natl Acad Sci USA*. 1983; 80:2346–2350. [PubMed: 6300911]
- Gran B, Zhang G-X, Rostami A. Role of the IL-12/IL-23 system in the regulation of T-cell responses in central nervous system inflammatory demyelination. *Crit Rev Immunol*. 2004; 24:111–128. [PubMed: 15581393]
- Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT. Interleukin 17-producing CD4⁺ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. *Nat Immunol*. 2005; 6:1123–1132. Doi: 10.1038/ni1254. [PubMed: 16200070]
- Hou W, Kang HS, Kim BS. Th17 cells enhance viral persistence and inhibit T cell cytotoxicity in a model of chronic virus infection. *J Exp Med*. 2009; 206:313–328. Doi: 10.1084/jem.20082030. [PubMed: 19204109]
- Jadidi-Niaragh F, Mirshafiey A. Th17 cell, the new player of neuroinflammatory process in multiple sclerosis. *Scand J Immunol*. 2011; 74:1–13. Doi: 10.1111/j.1365-3083.2011.02536.x. [PubMed: 21338381]
- Kriesel JD, Sibley WA. Editorial: The case for rhinoviruses in the pathogenesis of multiple sclerosis. *Mult Scler*. 2005; 11:1–4. [PubMed: 15732259]
- Laroche C, Michaud P. New developments and prospective applications for β (1,3) glucans. *Recent Pat Biotechnol*. 2007; 1:59–73. [PubMed: 19075833]

- LeibundGut-Landmann S, Gross O, Robinson MJ, Osorio F, Slack EC, Tsoni SV, Schweighoffer E, Tybulewicz V, Brown GD, Ruland J, Reis e Sousa C. Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. *Nat Immunol.* 2007; 8:630–638. Doi: 10.1038/ni1460. [PubMed: 17450144]
- Libbey JE, Fujinami RS. Potential triggers of MS. *Results Probl Cell Differ.* 2010; 51:21–42. Doi: 10.1007/400_2008_12. [PubMed: 19130026]
- Libbey JE, McCoy LL, Fujinami RS. Molecular mimicry in multiple sclerosis. *Int Rev Neurobiol.* 2007; 79:127–147. Doi: 10.1016/S0074-7742(07)79006-2. [PubMed: 17531840]
- Libbey JE, Tsunoda I, Fujinami RS. Studies in the modulation of experimental autoimmune encephalomyelitis. *J Neuroimmune Pharmacol.* 2010; 5:168–175. Doi: 10.1007/s11481-010-9215-x. [PubMed: 20401539]
- McCoy L, Tsunoda I, Fujinami RS. Multiple sclerosis and virus induced immune responses: Autoimmunity can be primed by molecular mimicry and augmented by bystander activation. *Autoimmunity.* 2006; 39:9–19. Doi: 10.1080/08916930500484799. [PubMed: 16455578]
- McIntosh M, Stone BA, Stanisich VA. Curdlan and other bacterial (1→3)-β-D-glucans. *Appl Microbiol Biotechnol.* 2005; 68:163–173. Doi: 10.1007/s00253-005-1959-5. [PubMed: 15818477]
- Petermann F, Korn T. Cytokines and effector T cell subsets causing autoimmune CNS disease. *FEBS Lett.* 2011; 585:3747–3757. Doi: 10.1016/j.febslet.2011.03.064. [PubMed: 21477588]
- Pullen LC, Miller SD, Dal Canto MC, Van der Meide PH, Kim BS. Alteration in the level of interferon-gamma results in acceleration of Theiler's virus-induced demyelinating disease. *J Neuroimmunol.* 1994; 55:143–152. [PubMed: 7829664]
- Rauch HC, Montgomery IN, Hinman CL, Harb W, Benjamins JA. Chronic Theiler's virus infection in mice: Appearance of myelin basic protein in the cerebrospinal fluid and serum antibody directed against MBP. *J Neuroimmunol.* 1987; 14:35–48. Doi: 10.1016/0165-5728(87)90099-3. [PubMed: 2433306]
- Theil DJ, Tsunoda I, Rodriguez F, Whitton JL, Fujinami RS. Viruses can silently prime for and trigger central nervous system autoimmune disease. *J NeuroVirol.* 2001; 7:220–227. Doi: 10.1080/13550280152403263. [PubMed: 11517396]
- Tsunoda I, Fujinami RS. Two models for multiple sclerosis: Experimental allergic encephalomyelitis and Theiler's murine encephalomyelitis virus. *J Neuropathol Exp Neurol.* 1996; 55:673–686. [PubMed: 8642393]
- Tsunoda I, Fujinami RS. Theiler's murine encephalomyelitis virus.. In: Ahmed, R.; Chen, ISY., editors. *Persistent viral infections.* Chichester, West Sussex, England. John Wiley & Sons, Ltd.; 1999. p. 517-536.
- Tsunoda I, Kuang L-Q, Theil DJ, Fujinami RS. Antibody association with a novel model for primary progressive multiple sclerosis: Induction of relapsing-remitting and progressive forms of EAE in *H2^S* mouse strains. *Brain Pathol.* 2000; 10:402–418. [PubMed: 10885659]
- Tsunoda I, Kuang L-Q, Tolley ND, Whitton JL, Fujinami RS. Enhancement of experimental allergic encephalomyelitis (EAE) by DNA immunization with myelin proteolipid protein (PLP) plasmid DNA. *J Neuropathol Exp Neurol.* 1998; 57:758–767. [PubMed: 9720491]
- Tsunoda I, Libbey JE, Fujinami RS. Sequential polymicrobial infections lead to CNS inflammatory disease: Possible involvement of bystander activation in heterologous immunity. *J Neuroimmunol.* 2007; 188:22–33. Doi: 10.1016/j.jneuroim.2007.05.012. [PubMed: 17604850]
- Tsunoda I, Wada Y, Libbey JE, Cannon TS, Whitby FG, Fujinami RS. Prolonged gray matter disease without demyelination caused by Theiler's murine encephalomyelitis virus with a mutation in VP2 puff B. *J Virol.* 2001; 75:7494–7505. Doi: 10.1128/JVI.75.16.7494-7505.2001. [PubMed: 11462022]
- von Herrath MG, Fujinami RS, Whitton JL. Microorganisms and autoimmunity: making the barren field fertile? *Nat Rev Microbiol.* 2003; 1:151–157. Doi: 10.1038/nrmicro754. [PubMed: 15035044]
- Yoshitomi H, Sakaguchi N, Kobayashi K, Brown GD, Tagami T, Sakihama T, Hirota K, Tanaka S, Nomura T, Miki I, Gordon S, Akira S, Nakamura T, Sakaguchi S. A role for fungal β-glucans and their receptor Dectin-1 in the induction of autoimmune arthritis in genetically susceptible mice. *J Exp Med.* 2005; 201:949–960. Doi: 10.1084/jem.20041758. [PubMed: 15781585]

Zepp J, Wu L, Li X. IL-17 receptor signaling and T helper 17-mediated autoimmune demyelinating disease. *Trends Immunol.* 2011; 32:232–239. Doi: 10.1016/j.it.2011.02.007. [PubMed: 21493143]

\$watermark-text

\$watermark-text

\$watermark-text

Fig. 1. Weight change and righting reflex as indicators of clinical disease following MNC transfer MNCs, isolated from the brains and spleens of VV_{PLP}-primed CFA/BP-challenged SJL/J mice, were expanded *in vitro* in the presence of CD3/CD28 beads and transferred into naïve SJL/J mice. Mice were followed for clinical signs of disease. (a) Mice receiving brain MNCs had a significantly greater weight gain at days 2, 4 and 9 post MNC transfer than mice receiving spleen MNCs alone. In contrast, mice receiving spleen MNCs alone had a significantly greater weight gain at day 17 post MNC transfer than mice receiving brain MNCs. *, $p < 0.05$; **, $p < 0.01$, (ANOVA). Shown are mean weight changes from day 0 $\pm$ standard errors of the means (SEM) for groups with 4 and 6 mice per group. (b) The mice receiving brain MNCs tended to have higher righting reflex scores than mice receiving

spleen MNCs alone over the 3 weeks post MNC transfer; however, these differences did not reach significance. Shown are means $\pm$ SEM for groups with 4 and 6 mice per group.

\$watermark-text

\$watermark-text

\$watermark-text

Fig. 2. Neuropathology following MNC transfer

MNCs, isolated from the brains and spleens of VV_{PLP}-primed CFA/*BP* challenged SJL/J mice, were expanded *in vitro* in the presence of CD3/CD28 beads and transferred into naïve SJL/J mice. Mice were euthanized at 3 weeks post MNC transfer and tissues were harvested, processed and stained with Luxol fast blue. Adjacent sections were immunostained for CD3. Neuropathology was scored as described in the Methods section. The mice receiving brain MNCs had higher neuropathology scores in both the brain and spinal cord, compared to mice receiving spleen MNCs alone, and this difference was significant in the brain. *, $p < 0.05$, (Mann-Whitney *U*). Shown are means + SEM for groups with 4 to 6 mice per group.

Fig. 3. Supernatant cytokine levels following CD3/CD28 bead stimulation of MNC cultures MNCs, isolated from the brains and spleens of VV_{PLP}-primed CFA/BP-challenged SJL/J mice, were expanded *in vitro* in the presence of CD3/CD28 beads. Supernatants were harvested and stored frozen until assayed. The concentrations of (a) IL-17A and (b) IFN- γ were measured in the cell culture supernatants by ELISA. No treatment (No Tx) and Con A stimulation of spleen MNCs served as negative and positive controls, respectively. The levels of both IL-17A and IFN- γ were higher in the brain MNCs expanded with CD3/CD28 beads than in the spleen MNCs expanded with CD3/CD28 beads.

Fig. 4. Weight change and righting reflex as indicators of clinical disease following curdlan administration

Groups of VV_{PLP}-primed SJL/J mice were challenged, 5 weeks post infection, with CFA/*BP*, curdlan/IFA or curdlan/PBS and followed for clinical signs of disease. **(a)** At day 6 post secondary challenge, the VV_{PLP}-primed curdlan/PBS challenged mouse group had significantly greater weight gain than both the VV_{PLP}-primed CFA/*BP* challenged and the VV_{PLP}-primed curdlan/IFA challenged mouse groups. At days 7, 11, 12 and 13 post secondary challenge, the VV_{PLP}-primed CFA/*BP* challenged mouse group had significantly greater weight loss than the VV_{PLP}-primed curdlan/IFA challenged and the VV_{PLP}-primed curdlan/PBS challenged mouse groups. **, $p < 0.01$; †, $p < 0.001$; ‡, $p < 0.0001$, (ANOVA, Fisher's PLSD). Shown are mean weight changes from day 3 $\pm$ SEM for groups with 5 to 19 mice per group. **(b)** The VV_{PLP}-primed CFA/*BP* challenged mouse group had significantly higher righting reflex scores than the VV_{PLP}-primed curdlan/IFA challenged and the VV_{PLP}-primed curdlan/PBS challenged mouse groups at days 12 and 13 post secondary

challenge. *, $p < 0.05$, (Mann-Whitney U). Shown are means $\pm$ SEM for groups with 5 to 19 mice per group.

\$watermark-text

\$watermark-text

\$watermark-text

Fig. 5. Neuropathology following curdian administration

Groups of VV_{PLP}-primed SJL/J mice were challenged, 5 weeks post infection, with CFA/*BP*, curdian/IFA or curdian/PBS. Mice were euthanized at 2 or 3 weeks post secondary challenge and tissues were harvested, processed and stained with Luxol fast blue. Adjacent sections were immunostained for CD3. Neuropathology was scored as described in the Methods section. The VV_{PLP}-primed curdian/PBS challenged mouse group tended to have lower neuropathology scores in both the brain and spinal cord in comparison to the VV_{PLP}-primed CFA/*BP* challenged and the VV_{PLP}-primed curdian/IFA challenged mouse groups. Shown are means + SEM for groups with 3 to 14 mice per group.

Fig. 6. Serum IL-17 levels following curdian administration

Groups of VV_{PLP}-primed SJL/J mice were challenged, 5 weeks post infection, with CFA/*BP*, curdian/IFA or curdian/PBS. Mice were bled upon sacrifice and the concentration of IL-17A was measured in the mouse sera by ELISA. The level of IL-17A in the sera of the VV_{PLP}-primed CFA/*BP* challenged mouse group was significantly lower than the level of IL-17A in the sera of both the VV_{PLP}-primed curdian/IFA challenged and the VV_{PLP}-primed curdian/PBS challenged mouse groups. *, $p < 0.05$, (ANOVA, Fisher's PLSD). Shown are means + SEM for groups with 9 to 16 mice per group.